Mr Mitchell Steven Norfleet, PA-C | |
102 W Gruenther Rd, Gretna, NE 68028 | |
(402) 332-2772 | |
(402) 332-5446 |
Full Name | Mr Mitchell Steven Norfleet |
---|---|
Gender | Male |
Speciality | Physician Assistant |
Experience | 20 Years |
Location | 102 W Gruenther Rd, Gretna, Nebraska |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225040900 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363AM0700X | Physician Assistant - Medical | 1156 (Nebraska) | Secondary |
363A00000X | Physician Assistant | 1156 (Nebraska) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Chi Health Bergan Mercy | Omaha, NE | Hospital |
Chi Health Lakeside | Omaha, NE | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Alegent Creighton Clinic | 1951210418 | 827 |
News Archive
PDL BioPharma, Inc. announced today that it closed a financing transaction with Durata Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.
Some women take a short break from using postmenopausal hormone therapy before getting their breasts screened for cancer with mammography. They hope to lower their risk of being called back afterward for unnecessary extra breast imaging. But taking a short break from hormones doesn't actually work for this purpose, according to the first large-scale randomized controlled trial to address the question. The READ (Radiological Evaluation and Breast Density) trial of more than 1,700 Group Health women is in the June 2, 2009 Annals of Internal Medicine.
OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.
Research published Online First in The Lancet provides new evidence that a substantial proportion of individuals with a clinical diagnosis of Familial Hypercholesterolaemia (FH) inherit a combination of small-effect changes in several genes (polygenic) rather than a large-effect mutation in a single gene (monogenic).
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Mr Mitchell Steven Norfleet, PA-C 7261 Mercy Rd, Omaha, NE 68124-2311 Ph: () - | Mr Mitchell Steven Norfleet, PA-C 102 W Gruenther Rd, Gretna, NE 68028 Ph: (402) 332-2772 |
News Archive
PDL BioPharma, Inc. announced today that it closed a financing transaction with Durata Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.
Some women take a short break from using postmenopausal hormone therapy before getting their breasts screened for cancer with mammography. They hope to lower their risk of being called back afterward for unnecessary extra breast imaging. But taking a short break from hormones doesn't actually work for this purpose, according to the first large-scale randomized controlled trial to address the question. The READ (Radiological Evaluation and Breast Density) trial of more than 1,700 Group Health women is in the June 2, 2009 Annals of Internal Medicine.
OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.
Research published Online First in The Lancet provides new evidence that a substantial proportion of individuals with a clinical diagnosis of Familial Hypercholesterolaemia (FH) inherit a combination of small-effect changes in several genes (polygenic) rather than a large-effect mutation in a single gene (monogenic).
› Verified 1 days ago
Alicia K Clough, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 720 Us-6, Gretna, NE 68028 Phone: 402-751-0600 | |
Miss Daina Clarissa Keehn, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 9723 S 232nd Cir, Gretna, NE 68028 Phone: 402-990-7822 | |
Linda Miodonski, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 102 W Gruenther Rd, Gretna, NE 68028 Phone: 402-332-2772 | |
Lynn M Kocian, PAC Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 11820 Standing Stone Dr, Gretna, NE 68028 Phone: 402-332-3903 Fax: 402-391-3076 | |
Mrs. Sarah Baugher Wallingford, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 17160 Middle Ln, Gretna, NE 68028 Phone: 402-517-1491 | |
Reem Al Turk Bryson, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 102 W Gruenther Rd, Gretna, NE 68028 Phone: 402-332-2772 Fax: 402-332-5446 |